Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions
The COVID-19 pandemic ignited research centered around the identification of robust
biomarkers and therapeutic targets. SARS-CoV-2, the virus responsible, hijacks the …
biomarkers and therapeutic targets. SARS-CoV-2, the virus responsible, hijacks the …
[HTML][HTML] Efficacy and limitations of repurposed drugs and vaccines for COVID-19
N Murmu, M Sarkar, S Dey, R Manna, S Roy… - Journal of Medicine …, 2023 - Elsevier
ABSTRACT COVID-19 is a contagious, severe acute respiratory disease caused by the
coronavirus named SARS-CoV-2. In this review, we have updated the nature and evolution …
coronavirus named SARS-CoV-2. In this review, we have updated the nature and evolution …
[HTML][HTML] Blood Stream Infections in COVID-19 Patients From a Tertiary Care Center in Lebanon: Causative Pathogens and Rates of Multi-Drug Resistant Organisms
SB Nahhal, J Zakhour, AH Shmoury, T Sawma… - … : Innovations, Quality & …, 2023 - Elsevier
Objective To report the microbiological profile of the pathogens implicated in blood stream
infections (BSI) in hospitalized coronavirus disease 2019 (COVID-19) patients and to …
infections (BSI) in hospitalized coronavirus disease 2019 (COVID-19) patients and to …
[HTML][HTML] Ivermectin-induced bacterial gut dysbiosis does not increase susceptibility to Pseudomonas aeruginosa lung infection but exacerbates liver damage
TCA Belo, NC de Melo Santos, BS Souto, CP Rosa… - Microbes and …, 2023 - Elsevier
Excessive use of medications, including the antiparasitic drug ivermectin, can lead to
bacterial gut dysbiosis, an imbalance in the intestinal microbiome, which in turn may …
bacterial gut dysbiosis, an imbalance in the intestinal microbiome, which in turn may …
Multi-Targeting Approach in Selection of Potential Molecule for COVID-19 Treatment
The coronavirus disease (COVID-19) is a pandemic that started in the City of Wuhan, Hubei
Province, China, caused by the spread of coronavirus (SARS-CoV-2). Drug discovery teams …
Province, China, caused by the spread of coronavirus (SARS-CoV-2). Drug discovery teams …
Beneficios en salud de un programa de optimización de antimicrobianos liderado por un farmacéutico en distintos niveles asistenciales
M Cantudo Cuenca - 2023 - digibug.ugr.es
Introducción La resistencia a los antimicrobianos está aumentando en todo el mundo y se
ha convertido en una de las amenazas más graves para la salud pública, siendo el uso …
ha convertido en una de las amenazas más graves para la salud pública, siendo el uso …
[PDF][PDF] The Rise and Fall of Hydroxychloroquine (HCQ) in COVID Era: A Therapeutic Journey and Synthetic Progress
GN Vaidya, A Venkatesh, DR Chatterjee, P Rana… - academia.edu
With no proven therapy against COVID-19, the repurposing of existing drugs is an ongoing
exercise. In this context, an antimalarial drug, hydroxychloroquine (HCQ) received …
exercise. In this context, an antimalarial drug, hydroxychloroquine (HCQ) received …
A COVID-19 associada a lesão renal aguda foi uma das principais causas de morte entre os pacientes hospitalizados em estado grave, pois as complicações renais …
LM dos Santos, DRBG da Silva… - Revista …, 2023 - ojs.revistacontemporanea.com
A COVID-19 associada a lesão renal aguda foi uma das principais causas de morte entre os
pacientes hospitalizados em estado grave, pois as complicações renais podem ocorrer …
pacientes hospitalizados em estado grave, pois as complicações renais podem ocorrer …
ADOÇÃO DE TERAPIAS MEDICAMENTOSAS E NÃO-MEDICAMENTOSAS NA INFECÇÃO DO SARS-COV-2
LS Neto, VA Ferreira - Revista Multidisciplinar em Saúde, 2023 - editoraintegrar.com.br
Objetivo: foi analisar os principais medicamentos utilizados pela população de uma cidade
de médio porte no interior do estado de Mato Grosso-Brasil, para prevenir e tratar a COVID …
de médio porte no interior do estado de Mato Grosso-Brasil, para prevenir e tratar a COVID …
[引用][C] Quantum Chemical and Informatics-Based Approaches for Probing Biomolecular Systems Toxicology
S Pandit, P Singh, R Parthasarathi - 2023 - Elsevier